COVID-19 Infection in Diabetic Patients

Overview

It was observed during the last period of COVID-19 pandemic that diabetic patients had a worse prognosis and more deteriorated clinical features than other patients

Full Title of Study: “Clinical Features of Diabetic Patients With COVID-19 Infection”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 20, 2021

Detailed Description

Diabetic patients infected with SAR-COV-19 were reported to have worse prognosis and faster deterioration in addition to higher rate for ICU admission when compared to other infected patients. In this study authors aim to investigate the certain cause for their case deterioration to be modified for better prognosis

Interventions

  • Other: no intervention as it is an observational study
    • both groups will be monitored for the disease progress or deterioration and mortality rate

Arms, Groups and Cohorts

  • control group
    • COVID-19 infected patients with no other comorbidities and they take the routine protocol from the Egyptian ministry of health
  • diabetic group
    • COVID-19 infected patients with diabetes comorbidity and they receive the routine protocol for covid treatment in addition to their hypoglycemic drugs

Clinical Trial Outcome Measures

Primary Measures

  • Investigation of bad prognosis cause for covid-19 diabetic patients
    • Time Frame: 30 days
    • number of diabetic patients with deteriorated case and to find the best hypoglycemic drug used for diabetic patients with covid-19 infection

Participating in This Clinical Trial

Inclusion Criteria

Patients infected with COVID-19 male or female 30 years old or more inpatients Exclusion Criteria:

  • have othe comorbidities other than type 2 diabetes mellitus pregnant women below 30 years old

Gender Eligibility: All

Minimum Age: 30 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Cairo University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Dalia K. Zaafar, lecturer of pharmacology – Cairo University
  • Overall Contact(s)
    • Dalia Zaafar, PhD, +201117922833, dr.moda88@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.